Dynavax Technologies Corp (DVAX)
11.21
+0.04
(+0.36%)
USD |
NASDAQ |
Apr 26, 16:00
11.20
-0.02
(-0.13%)
After-Hours: 20:00
Dynavax Technologies Research and Development Expense (Quarterly): 14.12M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 14.12M |
| September 30, 2023 | 14.12M |
| June 30, 2023 | 13.05M |
| March 31, 2023 | 13.60M |
| December 31, 2022 | 12.85M |
| September 30, 2022 | 12.96M |
| June 30, 2022 | 9.689M |
| March 31, 2022 | 11.10M |
| December 31, 2021 | 11.12M |
| September 30, 2021 | 6.186M |
| June 30, 2021 | 7.167M |
| March 31, 2021 | 7.758M |
| December 31, 2020 | 9.549M |
| September 30, 2020 | 8.521M |
| June 30, 2020 | 5.884M |
| March 31, 2020 | 4.653M |
| December 31, 2019 | 12.27M |
| September 30, 2019 | 12.66M |
| June 30, 2019 | 16.20M |
| March 31, 2019 | 21.21M |
| December 31, 2018 | 22.89M |
| September 30, 2018 | 16.82M |
| June 30, 2018 | 16.27M |
| March 31, 2018 | 18.97M |
| December 31, 2017 | 17.41M |
| Date | Value |
|---|---|
| September 30, 2017 | 16.42M |
| June 30, 2017 | 14.81M |
| March 31, 2017 | 16.34M |
| December 31, 2016 | 18.44M |
| September 30, 2016 | 23.23M |
| June 30, 2016 | 22.75M |
| March 31, 2016 | 20.07M |
| December 31, 2015 | 20.93M |
| September 30, 2015 | 24.10M |
| June 30, 2015 | 19.69M |
| March 31, 2015 | 22.22M |
| December 31, 2014 | 19.64M |
| September 30, 2014 | 28.07M |
| June 30, 2014 | 23.64M |
| March 31, 2014 | 13.23M |
| December 31, 2013 | 12.13M |
| September 30, 2013 | 11.77M |
| June 30, 2013 | 12.80M |
| March 31, 2013 | 14.16M |
| December 31, 2012 | 12.52M |
| September 30, 2012 | 12.85M |
| June 30, 2012 | 11.38M |
| March 31, 2012 | 12.40M |
| December 31, 2011 | 11.62M |
| September 30, 2011 | 11.78M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.653M
Minimum
Mar 2020
16.20M
Maximum
Jun 2019
10.71M
Average
11.12M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Supernus Pharmaceuticals Inc | 23.35M |
| Esperion Therapeutics Inc | 17.74M |
| Deciphera Pharmaceuticals Inc | 58.60M |
| Ligand Pharmaceuticals Inc | 5.488M |
| Pacira BioSciences Inc | 19.46M |